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Abstract Small bowel transplanta- 
tion (SBT) would, in theory, be the 
treatment of choice for patients suf- 
fering from the short bowel syn- 
drome. Although SBT has been done 
with a considerable degree of success 
in some centers [36,145], it is by no 
means an established or widely ap- 
plicable therapy for those with short 
bowelsyndrome. The small bowel is 
unique among vascularized organ 
grafts because it not only elicits a vi- 
gorous rejection reaction but is also 
capable of inducing graft-versus-host 
disease (GVHD). Rejection of the 
graft does not only lead to loss of 
function but also to bacterial translo- 
cation. The risk of fatalsepsis is ag- 
gravated by the immunosuppression 
given toprevent rejection. Here, the 
history of SBTis described, and re- 
cent developments in experimental 
and clinical SBT, as well as future 
prospects for this theoretically opti- 
mal treatment modality for patients 
dependent on total parenteral nutri- 
tion (TPN) for life, are outlined. 
Key words Small bowel 
transplantation 
Histoty 
In 1959, Lillehei et al. [73] described, for the first time, a 
technique for orthotopic small bowel transplantation 
(SBT) in the dog. Many experimental studies followed 
and several patients received a small bowel transplant. 
However, the initial enthusiasm for SBT waned when it 
became evident that rejection and sepsis were recurrent 
problems that could not easily be solved and when total 
parenteral nutrition (TPN) was introduced as satisfactory 
therapy for otherwise untreatable patients. With the in- 
troduction of the potent immunosuppressive agent cy- 
closporin A (CyA) came a renewed interest in SBT, which 
is presently on the verge of becoming an established pro- 
cedure in transplant medicine. 
rats from two inbred parent (P) strains and their offspring 
(FI), they were able to distinguish graft-versus-host dis- 
ease (GVHD) from rejection. Transplantation from P to 
F1 produces only GVHD, whereas in the reverse siutation 
only rejection occurs. The relevance of these one-way 
semiallogeneic models to the clinical situation, in which 
both GVHD and rejection may occur, is unceftain [114] 
and, hence, fully allogeneic combipations, in which the 
graft is transplanted from PI to P2, are used to study the 
possible interaction between GVHD and rejection. Synge- 
neic transplantation from P1 to P1 can be used to study the 
effects of ischemia and lymphatic and neural disruption 
while the immunologically induced traumas are circum- 
vented (Table 1). In large animals, syngeneic transplanta- 
tion finds its equal in autotransplantation, in which the ar- 
terial and venous blood supply are divided and reanasto- 
mosed, the lymphatics and nerves are disrupted, and the 
bowelis cut andreanastomosed [73,84,107]. 
With respect to the Dosition of the bowel, two models Experimental models of small bowel transplantation 
Anumberofmodelsare used tostudySBT,each havingits 
own advantages and disadvantages. Monchik and Russell 
[90] first used parent and F1 hybrid rats in SBT. By using 
areused.In~ne,thebowelisplaced heterotopically; there- 
cipient small bowel remains in situ, and the graft is placed 
as a Thiry-Vella fistula with both ends of the graft anasto- 
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GVHD Rejection Table 1 immunological reac- Model tions after small bowel trans- 
plantation P1 +P1 - - 
F1-P - + 
P+F1 + - 
Pl- tP2  + + 
mosedasstomasin the abdominalwall of the recipient.The 
oral end of the graft may also be ligated or placed as a 
duodenostoma, whereas the distal end is anastomosed 
end-to-side to the terminal ileum of the recipient bowel. 
In the orthotopic model, the recipient small bowel is 
resected and the graft is placed in continuity with the re- 
maining duodenum and terminal ileum of the recipient. In 
this model, recipient survival is dependent upon the func- 
tioning of the graft. Although orthotopic SBT (OSBT) 
may be the preferred model [38,68], the reported longer 
operative time and higher incidence of complications [62, 
631 have resulted in a number of studies in which hetero- 
topic SBT (HSBT) has been used [150]. In skilled hands, 
however, the operative time and technical success rate for 
both techniques are not significantly different [159]. Re- 
sults obtained after HSBT and OSBT are not comparable 
[38,68]. After HSBT, rejection of the graft is defined as 
the development of a palpable abdominal mass and ne- 
crosis of stomas [38,68]. However, the graft may become 
encapsulated and fibrotic rather than necrotic and perfor- 
ated, and the recipient may survive despite the graft loss, 
which makes the end point of rejection more difficult to 
define [38,123]. Moreover, probably due to a lack of intra- 
luminal nutrients, atrophy of the mucosa occurs [ 1511, and 
the permeability of these grafts 7 days postoperatively is 
significantly higher than after OSBT. Graft survival after 
HSBT can be prolonged more easily than after OSBT 
[38]. In conclusion, OSBT may be the preferred model for 
both immunological and functional studies. 
Venous drainage of the graft may be in the portal or in 
the systemic circulation. Although technically more de- 
manding [131], portoportal drainage is the more physio- 
logical route. Beneficial effects of this route on graft sur- 
vival have been reported [63,123], although they may be 
of minor importance [69]. Portocaval shunting may cause 
metabolic complications, such as a rise in blood ammonia 
levels, and liver atrophy. The effects of portocaval shunt- 
ing after SBT appear to be minor, and either type of ven- 
ous drainage may be used safely [53,63,123,131]. 
Lillehei et al. [73] were the first to describe a technique 
for functional bowel transplantation in the dog. After the 
bowel had been removed, it was autotransplanted and 
subsequently had good function. Different models of he- 
terotopic and orthotopic placement of the bowel, with 
either systemic or portal venous drainage, are used as pre- 
clinical models for the immunological and functional 
studies. Since pigs are inexpensive, easily cared for, and 
gain weight rapidly, they are also used in SBT [35,54,106]. 
Histology 
The sequence of histological changes after SBT is well 
defined, although there may be slight differences, de- 
pending on the model studied [46,76,90,120]. 
In our BN-to-WAG fully allogeneic, orthotopic total 
SBT model, early intestinal lesions on days 4-6 post-trans- 
plantation were characterized by mild infiltration of the 
lamina propria and submucosa by mononuclear cells and 
neutrophils and by mild multifocal deathof crypt epithelial 
cells. The number of mononuclear cells increased to 
moderate over a period of a few days, while only a few neu- 
trophils were seen after 6 days. Crypt cell death was also 
observed on days 7-12 post-transplantation, but it never 
became a prominent feature. Fibrin thrombi inmucosal ca- 
pillaries were observed with increasing frequency during 
the course of graft rejection. This was associated with ex- 
tensive necrosis of the mucosa at 11 and 12 days aftergraft- 
ing. Widespread thrombosis, resulting in ischemia, is prob- 
ably the principal cause of graft necrosis. Mononuclear 
cells accumulated around blood vessels in the mesentery. 
At  11-12 days post-transplantation, early changes in the 
arteries included endothelial hypertrophy, and this was fol- 
lowed by mild intimal proliferation and thrombosis. 
The mesenteric lymph node became rapidly depleted 
of lymphocytes, which were replaced by large mononu- 
clear cells, presumably macrophages, and increasing 
numbers of fibroblasts. 
Immunohistochernical changes generally predate his- 
tological ones. In rats, a huge number of macrophages are 
seen infiltrating the submucosa, peaking on day 7. In- 
creasing numbers of T cells are seen starting on day 3 in 
the submucosa, whereas their numbers are increased in 
the crypts on days 5 and 7 [44]. In humans, increased num- 
ber of macrophages and CD 4 + cells are found in the lami- 
na propria, and crypts express HLA-DR antigens [49]. 
Others have found pericryptic infiltrates of CD 3 +cells 
and HLA-DR expression on crypt enterocytes 3-5 days 
before histological changes became apparent [6] 
Immunosuppression with cyclosporin 
Before CyA became available, other immunosuppressive 
agents were used in attempts to prolong small bowel allo- 
graft survival. Taylor et al. [141] used high doses of aza- 
thioprine in the artificial model of transplantation of a 
small segment of small bowel as a Thiry-Vella fistula in the 
neck of dogs. Only marginal prolongation of graft survival 
was found. Preston et al. [104], using the same model, 
added prednisone to azathioprine and found prolonga- 
tion of graft survival from 9 to 27.5 days. Addition of anti- 
lymphocyte serum (ALS) to this regimen prolonged graft 
survival to a mean of 38 days [41]. 
Interest in SBT has been rekindled since the introduc- 
tion of the potent immunosuppressant CyA [57]. Reznick 
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Table 2 Use of FK 506 in rat small bowel transplantation. OSBT, Orthotopic small bowel transplantation; HSBT, heterotopic small bowel 
transplantation; pc, portocaval venous drainage; pp, portoportal venous drainage; nr, not reported 
Author Model‘ FK 506 dose Additonal treatment/ Survivalb (days) GVHD 
(mgikg) remarks 
Hoffmann et al. [45] 
Lee et al. [70] 
de Bruin et a1.’[10] 
Fukuzawa et al. [32] 
Murase et al. [Y4] 
Murase et al. [Y3] 
Santiago et al. [116] 
Tadeka et al. [I401 
Hatazawa et al. [42] 
Stangl et al. [136] 
Utsunomiya et al. [ 1471 
Yamataka et al. [158] 
HSBT-PC 
OSBT 
OSBT-PC 
HSBT-PC 
OSBT-pp 
OSBT-PC 
HSBT-PC 
HSBT 
OSBT 
nr 
OSBT-PC 
nr 
2 mg/kg, days 3-6 
2 mg/kg, days 3-6 + 
1 mg/kg, days 8-30, qod 
1 mg/kg, days 8-30, qod 
I mg/kg, days 8-30, qod 
2 mg/kg, days 0-4 
2 mg/kg, days 0, I ,  2,4,6 
2 mg/kg, days 0, 1,2,4,6 
0.3 mg/kg, days 0-14 
0.3 mg/kg, days 0-14 
0.15 mg/kg, days 0-13 
0.15 mg/kg, days 0-13 
0.64 mg/kg, days 0-13 
0.3 mg/kg, days 0-1 3 
1.0 mg/kg, days 0-13 
2.0 mg/kg, days 0-13 
0.3 mg/kg, days 0-13 
None 
0.32 mg/kg. days 0-13 
0.32 mgikg, days 0-13 
1.0 mglkg per day, 
8 weeks, s. c. 
10 mgikg CyA, days 0-5 
10 mgikg CyA, days @5 
One-way rejection 
One-way GVHD 
5 Gy donorirr 
1 .O mglkg, 
days - 8- - 4 
1.0 mg/kg, 
days - 8- - 4 
+ DST, day - 8’ 
donor 2 mg/kg FK, 
days -3, -2, - 1 
donor 2 mg/kg FK, 
days - 3, - 2, - 1 
minor H C  incom- 
patible 
major H C  incom- 
patible 
0.1 mgikg, days 0-29 
0.3 mg/kg, days 0-29 
0.5 mg/kg, days 0-29 
1.0 mgikg, days 3-5, i. p. 
1.0 mgikg, days 3-5, i. p., 
+ cL-ICAM-l,1 mg/kg, days 1-3 
FK 506,2 mg/kg, 
days 13-15 
34.9 ? 30.8 
50.6 ? 46.5 
83.0 k 82.6 
188.0 k72.1 
> 180 
28.5 k 6.8 SE 
31.1 k5.7 SE 
9.8 i 2.8 
62.2 k 33.6 
44.5 median 
“20-30 days” 
121, median 
6.8 k 0.8 
12.4 k 8.4 
17.4 k 4.7 
41.2 i 3.8 
12.2 k 1.9 
80 % > 175 
38.0 ? 6.3 
“ > 8 weeks” 
27.3 k 4.8 
> 270 
13.4 ? 3.07 
34.6 ? 12.79 
32.6 ? 26.16 
“ > 20” 
“ > 20” 
None 
None 
None 
None 
Severe 
None 
nr 
nr 
12.5 Yu 
Mild, self-limitingd 
Severe 
None 
nr 
nr 
nr 
nr 
nr 
nr 
None 
None 
nr 
nr 
nr 
nr 
nr 
a Fully allogeneic model, unless otherwise stated. FK was adminis- 
tered intramuscularly, unless otherwise stated 
Mean survival in days, unless otherwise indicated 
et al. [lo81 first reported prolongation of graft survival to 
a mean of 90.6 days after intramuscular (i.m.) administra- 
tion of 25 mg/kg per day. Many dogs died of pneumonia, 
perhaps due to the malnutrition caused by chronic rejec- 
tion of the grafts or due to the high dose of CyA. Discour- 
aging results in both dogs and pigs have also been re- 
ported by others [105]. 
In both unidirectional and fully allogeneic rat models, 
CyA is able to significantly prolong small bowel allograft 
survival [122]. This is highly dependent upon the rat strain 
DST + donor-specific blood transfusion 
Murase et al. 1991: mild, self-limiting GVHD in BN-to-Lew com- 
bination, severe GVHD in Lew-to-BN combination 
combination used. We have shown that in the BN-to- 
WAG rat donor-host combination, long-term allograft 
survival is easy to achieve using short courses of CyA, 
whereas in the reverse WAG-to-BN model, CyA has only 
a limited efficacy in prolonging graft survival [9]. In unidi- 
rectional P-to-F1 hybrid models, CyA appears to be less 
effective in preventing GVHD [58]. 
In large animal models, prolongation of graft survival 
is hard to achieve, but continuous intravenous (i.v.) infu- 
sion of CyA has been shown to result in long-term allo- 
so 
graft survival (122 f 33 days) in pigs, without any animals 
dying from rejection [34]. These results were achieved 
with 15 mg/kg CyA given i. v. for 7-10 days, followed by 
30 mg/kg per day orally, tapered to 15 mg/kg over 3-4 
months. However, high CyA blood levels of approxi- 
mately 600-700 ng/ml were measured that could lead to 
toxicity in the kidney [28] and bowel [19] and to an unac- 
ceptably high risk of developing malignancies [loo]. Re- 
cently, it was reported that MHC matching prolonged 
survival of segmental ileal grafts in nonimmunosup- 
pressed beagle dogs [43] and that graft rejection can be 
prevented with CyA when donor and recipient are fully 
MHC-matched: CyA dosages in this group were 15 mg/ 
kg i. m. from 1 day before surgery until the end of the 1st 
postoperative week and 30 mg/kg per day orally until 
day 200 post-transplantation. Recipients of an MHC- 
matched graft survived for a mean of 211 days without 
signs of rejection during CyA therapy. MHC-mis- 
matched dogs survived for a mean of 113 days with four 
of six animals showing rejection that occurred during 
CyA treatment [88]. 
Pretransplant CyA treatment (pretreatment) of the re- 
cipient is associated with a reduced incidence of acute re- 
jection in kidney transplantation [47]. Moreover, Kahan 
et al. [51] and Rogerson et  al. [110] found that low plasma 
CyA levels in the early postoperative period are associ- 
ated with a higher incidence of rejection following human 
renal transplantation. However, in an experimental rat 
study we were unable to significantly prolong small bowel 
allograft survival after preloading the recipient with high- 
dose CyA, as compared to postoperative immunosup- 
pression only, although no acute rejection occurred (un- 
published data). It is generally thought that oral adminis- 
tration of CyA should be avoided [57] since the disrupted 
lymphatics of the graft are unable to transport this lipo- 
philic drug to the blood. Although we have shown that ab- 
sorption of orally administered CyA after total small 
bowel resection is severely impaired [ l l ] ,  we found no 
lowered plasma trough levels in the 1st week post-trans- 
plantation. This finding is consistent with observations by 
Aeder et al. [l] and LaRosa et al. [64], who found that oral 
and intraluminal CyA absorption within 1 week after 
transplantation did not differ significantly from preopera- 
tive or control values. This indicates that there must be an 
alternative mechanism by which CyA is delivered to the 
blood. By administering CyA intraperitoneally to normal 
dogs, Cohen et  al. [17] have shown that some absorption 
may take place via the peritoneum. It is possible that after 
transplantation CyA in the lymph leaks into the perito- 
neal cavity through the disrupted lymphatics and is sub- 
sequently reabsorbed. Thus, even before lymph vessel 
continuity is re-established 4-10 weeks post-transplanta- 
tion, as is shown to happen in different models [61,113, 
1211, orally administered CyA is absorbed. It has, how- 
ever, been shown that CyA absorption is highly variable 
and unpredictable during the early postoperative period 
and, moreover, that rejection can impair the ability of the 
graft to absorb CyA [17]. Therefore, it seems justified to 
advocate parenteral administration as the main route, es- 
pecially in the first months after transplantation. Whether 
concomitant oral treatment can be of benefit due to local 
immunosuppressive effects needs to be investigated. 
Other fonns of immunosuppression 
FK 506 and rapamycin (RAPA) are both macrolides pro- 
duced by Streptomyces species with potent immunosup- 
pressive activity [14]. FK 506, like CyA, counteracts mi- 
togenic or antigenic stimulation at an early stage of T-cell 
activation, whereas RAPA intervenes in events more 
closely related to DNA synthesis. All three drugs exert 
their action via a class of binding proteins known as im- 
munophilins, which possess cis-trans peptidyl prolyl 
isomerase activity. There is evidence that FK 506 and 
RAPA bind to the same binding site, whereas CyA binds 
to the similar, but nonidentical, cyclophilin. Probably as a 
result of this, RAPA has been shown to antagonize the 
FK 506-induced inhibition of T-cell proliferation, and 
FK506 has been shown to antagonize the action of 
RAPA, although potentiation of either drug may be 
achieved using equimolar concentrations of the two 
agents. Combinations of CyA and FK 506 or RAPA in- 
variably result in a greater inhibition of mitogen and al- 
loantigen-induced T-cell responses. 
RAPA suppresses a wider spectrum of T- and B-cell ac- 
tivation pathways than FK 506 or CyA. Interest in these 
two agents for use in SBT is a direct result of the potency 
of RAPA and FK 506 in prolonging graft survival [144]. 
FK 506 
Hoffman et al. [45] performed an extensive study on the 
use of FK 506 for SBT in rats (Table 2). They showed that 
long courses of FK 506 are more effective than CyA in the 
prevention of acute rejection and let al GVHD in semial- 
post-transplantation prevented rejection in the fully al- 
logeneic ACI-to-Lew model. In the model used, a 
20 times higher dose of CyA was needed to obtain com- 
parable survival times. No clinical GVHD was observed. 
Using the BN-to-Lew rat model, Lee et  al. [70] found 
similar results, while Stangl et al. [136] showed in the same 
model that FK 506 is able to reverse an ongoing chronic 
rejection process. We were unable to find superior immu- 
nosuppressive effects of short-course FK 506 over CyA 
using the fully allogeneic WAG-to-BN rat strain combi- 
nation [lo]. Moreover, after FK 506 treatment, severe 
GVHD was seen. This was also observed by Murase et al. 
[94] in the BN-to-Lew combination giving 0.15 mg/kg for 
14 days. Hatazawa et al. [42], on the other hand, observed 
logeneic models. Short courses o 8 2 mg/kg on days 0-6 
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prolonged survival after administration of 1 mg/kg per 
day for 8 weeks in the same model. 
Masutani et al. [82] found in a P-to-F1 hybrid model 
that 14 days after HSBT using 0.32 mg/kg per day, FK SO6 
animals showed no histological signs of GVHD, and Mar- 
kus et al. [79] showed that FK SO6 is able to reverse on- 
going GVHD after bone marrow transplantation better 
than CyA and RAPA. 
Rapam y cin 
Continuous i.v. administration of 0.80 mgikg of RAPA 
for 14 days was shown to significantly prolong allograft 
survival [138]. Using Lew and (LBN) F1 hybrid one-way 
models, it was shown that RAPA is able to suppress both 
isolated rejection and GVHD, although its effect on 
GVHD is less potent than on rejection [S2]. Chen et al. 
[15], however, found RAPA to be equipotent in suppres- 
sing isolated rejection and GVHD in the same model. 
They also showed that RAPA is synergistically effective 
with CyA. Similar immunosuppressive efficacy as with 
CyA was achieved with a five times lower dose of RAPA 
after fully allogeneic rat SBT [138]. No toxicity was re- 
ported in these studies. 
Both FK SO6 and RAPA may prove to be the more po- 
tent, less toxic immunosuppressants needed for successful 
clinical SBT, but this has yet to be evaluated clinically. 
lmmunomodulation 
It has been widely recognized that preconditioning of the 
recipient with donor-specific blood transfusions (DST) 
may lead to prolongation of allograft survival in both ex- 
perimental [80] and clinical [97] transplantation. In the 
BN-to-WAG rat donor-host combination, DST are very 
effective in prolonging heart and kidney graft survival [go]. 
However, three pretransplant DST had no effect on total 
or segmental SBTin thismodel. WhenDSTwascombined 
with low-dose CyA administration, no additional prolon- 
gation of graft survival could be measured [8]. Similar re- 
sults were reported by Fecteau et al. [3O]. In contrast, Mar- 
tinelli et al. [Sl] did find a synergistic effect of CyA and 
DST,andwithFK 506,DSTactssynergisticallyaswell[32]. 
These findings indicate that DST may contribute to the 
prevention of rejection, but more studies are needed to 
determine whether DST can be a therapeutic option in 
living related SBT. 
Ultraviolet B (UV-B) irradiation of transfused cells in- 
tensifies the effects of DST in rat transplantation models. 
UV-B-irradiated leukocyte transfusions in combination 
with short-term, low-dose CyA immunosuppression is 
significantly efficacious in prolonging small bowel allo- 
graft survival. The mechanism includes, at least in part, a 
component of donor-specific unresponsiveness [ 1571. 
Graft-versus-host disease 
after small bowel transplantation 
Monchik and Russel [90] first showed that transplanta- 
tion of the small bowel may produce a lethal GVHD in P- 
to-F1 hybrid rat models. This GVHD shows histological 
similarities to that induced by bone marrow transplanta- 
tion [92] and is caused by T lymphocytes originating from 
the transplanted gut and its mesenteric lymph nodes [58, 
1491. Clinically, it is characterized by dermatitis, alopecia, 
a hunched posture and, eventually, death of the animal. 
Observations in unidirectional GVHD or rejection mod- 
els are of uncertain relevance to the clinical situation, in 
which a two-way reaction between rejection and GVHD 
may occur [57]. In fully allogeneic SBT, rejection rather 
than GVHD seems to predominate [31,69,90]. In some 
fully allogeneic models, 30 %-SO % of the animals show 
clinically overt GVHD, distinguished from that in the 
one-way model by its nonlethal, short-lived nature. Little 
is known about the interaction between rejection and 
GVHD in these models. Cohen et al. [16] investigated the 
effect of graft irradiation with 0.5 and 1.5 Gy prior to 
transplantation in a canine small bowel allograft model. 
They found that pretreatment with 1 .S Gy leads to rejec- 
tion of the small bowel allografts in 9.2 days. Pretreat- 
ment with 0.5 Gy, however, prolonged graft survival to a 
mean of 28 days. Therefore, they hypothesized that there 
is a balance between rejection and GVHD, and that the 
development of subclinical GVHD after 0.5 Gy irradia- 
tion results in prolonged graft survival. 
Since the early 1960s it has been known that GVHD 
depresses the host’s immunological reactivity [48]. This is 
best shown by clinical results obtained with T-cell-de- 
pleted bone marrow transplantation. On the one hand, 
T-cell depletion significantly reduces acute GVHD; on 
the other hand, it substantially increases graft rejection 
[137]. GVHD is also known to be immunosuppressive 
after experimental spleen, cell, and small bowel trans- 
plantation [35]. 
Histopathologically, GVHD is characterized, by a loss 
of the normal architecture of the spleen, lymph nodes, and 
thymus [22,35,124]. This leads to ptbfound immunosup- 
pression with impaired humoral and cell-mediated im- 
mune responses [35]. This immunosuppression probably 
accounts for the observed in vivo balance between rejec- 
tion and GVHD. 
Diflo et al. [26] observed a short, sublethal GVHD ap- 
proximately 4-6 weeks after fully allogeneic transplanta- 
tion in immunosuppressed animals. Donor pretreatment 
with ALS completely eliminated GVHD but had no ef- 
fect on graft survival in these immunosuppressed hosts. 
Gundlach et al. [39] found that mesenteric lymphadenec- 
tomy, a method that has been shown to eliminate GVHD 
[102], does not influence the course of acute graft rejec- 
tion in nonimmunosuppressed recipients. CyA was not ef- 
fective in preventing chronic rejection following mesen- 
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teric lymphadenectomy, whereas the same dosage of CyA 
fully prevented rejection of normal small bowel grafts. 
They suggested that the absence of an immunosup- 
pressive effect caused by a GVH reaction had led to 
chronic rejection in this model. 
We showed that irradiation of the donor with 10 Gy 
1 day before fully allogeneic SBT in the WAG-to-BN rat 
model completely eliminated GVHD and significantly 
shortened survival times [114]. Moreover, CyA treatment 
of the recipient was unable to completely override this ef- 
fect [115]. Pretreatment of the donor with ALS also elimi- 
nated clinical GVHD and led to significantly accelerated 
rejection [12]. When our recipients of a graft pretreated 
with ALS received immunosuppressive treatment with 
CyA, no adverse effect on graft survival was seen any 
more, whereas clinical GVHD remained suppressed. This 
important finding is in accordance with earlier findings 
from our laboratory [115]. The usefulness of manipulating 
this balance for future clinical SBT remains to be estab- 
lished since it is as yet unclear whether this balance theory 
is a rat strain-dependent phenomenon and whether 
GVHD will even be a clinical problem. 
Prevention of GVHD in SBT often implies reducing 
the immunogenicity of the graft also. In attempts to con- 
trol both rejection and GVHD, reducing the immunoce- 
nicity and, consequently, diminishing the number of leu- 
kocytes in the graft, has been carried out. Moreover, in the 
recipient, the immunosuppression used to prevent rejec- 
tion also suppresses GVHD, although in semiallogeneic 
rat models CyA appears to be less effective in preventing 
GVHD than in preventing rejection. FK 506 may even 
enhance GVHD [lo, 941. 
Several donor pretreatment modalities have been 
shown to abrogate or diminish clinical GVHD following 
experimental SBT. Total body irradiation of the donor 
prior to transplantation completely eliminates GVHD 
[23,67,90], as does pretreatment of the donor with ALS 
[130], mesenteric lymphadenectomy [23], and reducing 
the length of the graft [55]. 
High levels of the cytokine tumor necrosis factor alpha 
(TNFa) are measured in rats with lethal GVHD after 
SBT in a P-to-F1 GVHD model [103]. Blocking of TNFa 
activity reduces the mortality of GVHD after experimen- 
tal bone marrow transplantation and prevents skin and 
gut lesions of GVHD [loll.  This suggests that anti-TNFa 
antibody therapy could be helpful in reducing the severity 
or lethality of GVHD. Other cytokines may also be in- 
volved in the pathogenesis of GVHD [9l] and are impor- 
tant in graft rejection as well. Anticytokine therapy might, 
therefore, prove to be valuable in concert with other im- 
munosuppressive modalities. 
Graft physiology 
The small bowel exhibits nutritional, motor, hormonal, 
and immunological functions. After transplantation, 
changesin these functions may be expected for several rea- 
sons including the ischemia, lymphatic disruption, and de- 
nervation caused by the transplant procedure, the immu- 
nological processes arising after allogeneic transplanta- 
tion, and the immunosuppressive drugs given. The small 
bowel transplant must be able to overcome the symptoms 
of short bowel syndrome. In the adult recipient, long-term 
prevention of malnutrition, and inchildren, normalgrowth 
and development followed by long-term prevention of 
malnutrition, are prerequisites for successful clinical SBT. 
Nutritional function 
A sensitive functional test is whether a small bowel trans- 
plant recipient is able to grow and develop normally. Sev- 
eral studies have shown that rats are able to gain weight 
normally after allogeneic total SBT [ll, 1251. However, 
rats grafted with a segmental small bowel transplant may 
develop impaired nutritional parameters [125] or grow 
suboptimally [ l l ,  961, although Kirsch et al. [59] have 
shown that there were no significant differences in growth 
between sham-operated rats, animals with 50 % of their 
bowel (jejunum) intact, and animals transplanted ortho- 
topically with 50 % of their total bowel length of jejunum 
150 days post-transplantation. Moreover, just like the na- 
tive gut after bowel resection, the transplanted intestine is 
capable of adaptation (i. e., increased bowel diameter and 
increased villus height) [59]. In dogs, conflicting data have 
been reported. Long-term surviving, allografted dogs 
maintain their preoperative body weight but have only 
slightly better nutritional parameters than dogs with short 
gut syndrome [27]. Weight after transplantation of a 100- 
cm-long segmental ileal allograft was maintained at 88 % 
of its preoperative weight [B]. Autotransplanted dogs did 
not attain their preoperative weight until 1 year after 
transplantation [107]. Moreover, it has been reported that 
substantial nutritional disturbancedan be expected from 
lymphatic and neural division alone [3]. Recently, it was 
shown that autotransplanted adult dogs regain their pre- 
operative weight within 1 year after transplantation. One 
year post-transplantation, these animals still had elevated 
stool moisture content and developed steatorrhea and 
impaired D-xylose absorption [143]. However, MHC- 
matched, CyA-treated recipients of a 45- to 65-cm-long 
allograft of terminal ileum did not differ in growth or fecal 
fat content from sham-operated controls, indicating ade- 
quate nutritional function (Meijssen et al., submitted). In 
young pigs, total small bowel allografts are able to ade- 
quately sustain the recipients’ growth at a rate com- 
parable to that of normal controls [34]. Porcine segmental 
jejunal allografts comprising approximately 25 % of the 
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small bowel length are incapable of doing the same; by 
180 days after transplantation animals had increased their 
weight by only 40 Yo [56], as compared to more than 100 YO 
in 4 weeks in Grants’ animals. From these studies it seems 
that, from a nutritional point of view, allotransplantation 
will be possible. Taking into account its limitations (living 
related donation, abdominal size), as much bowel length 
as possible should be transplanted. More studies are 
needed to determine whether long-term functioning of 
SBT is feasible in both juvenile and adult recipients as op- 
posed to long-term total parenteral nutrition, and how 
compromised functions may be restored. 
Immune function 
The gut mocosa has an important barrier function with re- 
gard to luminal food antigens and pathogens [5]. It is con- 
stantly challenged by microbial and food antigens, and its 
responses to these stimuli must be appropriate; infections 
must be limited but, at the same time, the integrity of the 
vulnerable mucosa must not be compromised. Intestinal 
immunity was first observed when protective “coproanti- 
bodies” were found in stools of orally immunized rabbits. 
However, the vulnerable gut mucosa should also be pro- 
tected against potentially harmful reactions to harmless 
antigens. Indeed, suppressive mechanisms after immuni- 
zation with harmless antigens have been observed and are 
called “oral tolerance” [146]. How the suppressive and in- 
ductive immunoregulatory mechanisms are established in 
the intestine is still not clear. The secretory immunoglo- 
bulin (Ig) system is the major effector mechanism of mu- 
cosal immunity. Approximately 70 YO -80 % of all Ig is pro- 
duced by B lymphocytes in the mucosa of the small and 
large bowel. This secretory Ig, which is mainly IgA, is 
transported to the gut lumen through the epithelial cells 
of Lieberkiihn’s crypts. 
Numerous T lymphocytes are localized in the gut epi- 
thelium. In contrast to the lamina propria T lymphocytes, 
these intraepithelial lymphocytes (IEL) are in direct line 
with macromolecules in transit across the epithelium [29]. 
Their function is still obscure, but they are thought to play 
a role in cytotoxic as well as suppressive immune reac- 
tions. Apart from these solitary cells, the gut also contains 
organized solitary lymph nodes and lymph node aggre- 
gates: Peyer’s patches. These are probably the major site 
of antigen presentation and commitment to slgA syn- 
thesis in the mucosal-associated lymphoid tissue. Sen- 
sitized and committed cells migrate via the mesenteric 
lymph node and the bloodstream to distant gut. IgA-pro- 
ducing cells may also migrate to other mucosal surfaces 
that are part of the mucosal-associated lymphoid tissue, 
such as the lung, mammary glands, salivary glands, and la- 
crimal glands [ 1461. 
The immune function of bowel transplants is largely 
unknown. Both in humans [50] and in experimental ani- 
mals [66] it was found that graft lymphocytes are replaced 
by cells of recipient origin without the occurrence of re- 
jection. Xia and Kirkman [154] found no differences in 
graft total slgA production after syngeneic and semial- 
logeneic SBT in rats. Immunosuppression with CyA had 
no effect on the total sIgA production. However, allo- 
grafted animals treated with CyA failed to produce signi- 
ficant amounts of specific anticholera toxin sIgA when 
challenged with choleratoxin at the time of transplanta- 
tion. The specific immune response to cholera toxin re- 
mained completely suppressed as long as the animals 
received CyA [156]. When allografted animals were 
boosted with choleratoxin 7 days post-transplantation, 
after having been primed 1 week before transplantation, 
normal sIgA levels were measured [155]. The presence of 
(part of) the recipient’s colon could be important since it 
also contributes to gut mucosal immunology. The effect of 
different immunosuppressive agents on graft immune 
function needs to be investigated. 
Motor function 
The motility of the normal, intact upper gut has been well 
characterized. The stomach and small intestine display 
distinct patterns of motility during fasting and feeding. 
During the fasting or interdigestive period, the upper gut 
shows a spontaneous and recurrent cyclic pattern of mo- 
tility, called the migrating motor complex (MMC) or in- 
terdigestive myoelectric complex. Feeding interrupts this 
MMC and induces a less well-defined, noncyclic pattern 
of intermittent, low-amplitude contractions that persist 
for a variable period of time, depending on the type and 
amount of nutrient. These motor patterns are physiologi- 
cally important. During fasting, the MMC sweeps nondi- 
gestable intraluminal debris from the stomach and small 
intestine (“intestinal housekeeping”). The change in 
motor pattern caused by feeding is believed to maximize 
the mixing of food and to facilitate its absorption. 
Schiller et  al. [119] noted alterations in the mptility of 
jejunal segments transplanted in the neck of recipient 
dogs. In Lew rats that had received a dgmental syngeneic 
SBT, basal electrical rhythm of the graft was not observed 
for approximately 2 days after transplantation and did not 
attain the level of normal rats for at least 3 weeks. MMC 
was not observed in the transplanted segment until post- 
operative day 11 and became constant starting on post- 
operative day 16 [148]. In a dog model of small bowel 
autotransplantation, in which all extrinsic neural and lym- 
phatic connections to the jejunoileum were transected, 
the MMC was present, although the coordination be- 
tween the innervated duodenum and the denervated 
jejunoileum, present in the normal gut, was lacking [118]. 
The presence of MMC is of importance since its intestinal 
housekeeping function is thought to be essential in pre- 
venting bacterial overgrowth, a situation also encoun- 
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tered after SBT (see below). Feeding or infusing the puta- 
tive postprandial peptide hormones cholecystokinin or 
pentagastrin induced a normal “fed” pattern of contrac- 
tions [118]. This implies that the intrinsic nerves of gut are 
capable of generating these motor patterns without input 
from the central nervous system. 
Hormonal function 
A number of hormones are produced by cells scattered 
diffusely throughout the length of the gut. The physiologi- 
cal role of these peptides is still being evaluated. Intra- 
luminal levels of vasoactive intestinal peptide, somato- 
statin, and substance P are stable from 4 days after synge- 
neic SBT to 1 year post-transplantation. During rejection, 
however, lowered levels of these hormones have been 
found [142]. LaRosa et al. [65] reported that SBT does not 
alter the baseline levels of serotonin and substance P or 
their response to stimuli. 
Monitoring of graft rejection 
Unlike renal, hepatic, and pancreatic grafts, intestinal 
grafts have, as yet, no specific, distinguishing serum mar- 
kers to diagnose rejection. Histology remains the gold 
standard for the diagnosis of rejection [86], although this 
method has several short-comings. Full thickness biopsies 
from the graft have to be taken from cutaneous stomas to 
reliably recognize rejection [89], which involves the risk of 
graft perforation. Multiple biopsies are necessary because 
rejection shows a patchy character and may be easily 
missed [25, 84, 1201. In view of these limitations, several 
small bowel function tests have been studied to determine 
their usefulness as markers for rejection. Function tests of 
the graft that need biopsy material from the graft, such as 
the determination of brush border enzyme activity [87, 
1271, have the same disadvantage of being dependent 
upon the presence of an enterostoma. Moreover, they do 
not detect rejection at an earlier stage than does histology. 
Functional tests, functional absorption tests, and putative 
serum markers of rejection must be at least as sensitive 
and as specific as histology in order to be considered an al- 
ternative to histology. 
In order to be absorbed, the disaccharide maltose must 
be split into glucose by the brush border enzyme maltase. 
This glucose is subsequently absorbed and raises the 
blood glucose level. In this way, the maltose absorption 
test can be performed as a glucose tolerance test. Billiar et 
al. [4] studied this test in rats and found that a reduction in 
maltose absorption preceded histological changes by 1- 
2 days. They concluded that this test is a reliable, repro- 
ducible, and sensitive method for monitoring rejection. 
Intestinal absorption of water, sodium, glucose, 
alanine, and lauric acid have also been proposed as early 
serum markers. These substances require active transport 
by the mucosa, and significant decreases in their absorp- 
tion were found when the first changes in histology were 
present [25]. 
Intestinal permeability to T r - E D T A  is increased dur- 
ing rejection. In rats, a twofold increase was measured at 
the time minimal histological signs of rejection were pres- 
ent 1371. Assessment of urinary ”Cr-EDTA as a measure 
of intestinal permeability has already proved its useful- 
ness, permitting early detection and treatment of an acute 
rejection episode after clinical small bowel-liver trans- 
plantation [36]. 
Monocyte-macrophage procoagulant activity is a 
measure of immune activation of mononuclear cells. 
Measured in peripheral blood mononuclear cells, elev- 
ated levels were observed before histological changes of 
allograft rejection and remained high throughout the 
course of rejection. This test appears to be an accurate 
serum marker for the detection of rejection [54,132]. 
The lysosomal acid hydrolase N-acetyl hexosamini- 
dase (NAH) is elevated in serum in association with intes- 
tinal ischemia. A study performed in rats suggested that 
determination of serum NAH is a simple and rapid test 
that can prove useful as a serum marker for small bowel 
allograft rejection [77]. In contrast to this report, Meijssen 
et al. [85] found in a dog model that a significant rise in 
NAH occurred after histological changes related to acute 
rejection were visible. 
Transepithelial potential difference has been studied 
to determine its value as a diagnostic tool for the early de- 
tection of rejection. Madara and Kirkman [76], using anin 
vitro method, found that a decreased spontaneous trans- 
epithelial potential difference, which is an index of base- 
line active transport resulting from electrogenic sodium 
absorption and chloride secretion, correlated with histo- 
logical signs of rejection. Sodium-coupled glucose ab- 
sorption, which is an index of villus function, and theo- 
phylline-stimulated chloride secretion, which mainly 
measures crypt cell function, decreased when structural 
changes indicative of rejection became apparent. Lee et 
al. [71] found that changes in basal transepithefial poten- 
tial difference parallelled, and oftep preceded, histologi- 
cal changes of rejection. Because of the invasive nature of 
their method, they did not consider it a practical clinical 
tool. In a model of canine small bowel autotransplanta- 
tion, Meijssen et al. [86] developed a noninvasive method 
using a double balloon catheter that was inserted in an en- 
terostomy and isolated a loop of bowel in which electro- 
physiological measurements could be performed. It was 
shown that in vivo electrophysiological parameters pro- 
vide a useful tool in the assessment of small bowel auto- 
transplants. A reduction in transepithelial potential dif- 
ference preceded degenerative mucosal changes in the 
graft. It was subsequently found that following allotrans- 
plantation, electrophysiological parameters correlate 
with histological alterations of acute rejection, thus dem- 
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onstrating that serial monitoring of transepithelial poten- 
tial differences is a noninvasive method for detecting 
smal1 bowel allograft rejection that circumvents the disad- 
vantages of histological monitoring [84]. 
Preservation 
At present, no consensus exists about the method of 
choice or preservation solution for a small bowel graft, 
nor is it known what maximal ischemia time is tolerable. 
Euro-Collins solution may be the best preservation fluid 
for the canine small bowel, as compared to University of 
Wisconsin (UW) solution or Ringer's lactate [40], but in 
rats UW solution seems to be the most effective preserva- 
tion solution [129]. The mucosa of the small bowel is very 
susceptible to ischemia and reperfusion injury [99]. Vas- 
cular and luminal perfusion of the graft alone without cold 
ischemia leads to mucosal injury in rats that is completely 
healed 24 h after transplantation. After 5 h of cold ische- 
mia at 4 "C using UW or Sacks' solution, the mucosa of the 
graft was significantly injured, but 24 h after transplanta- 
tion there was complete healing of the mucosa. However, 
18 h of cold ischemia led to severe injury that was still 
present 24 h after transplantation [98]. 
The pathophysiology of reperfusion injury involves the 
formation of oxygen-derived free radicals [99]. It has been 
shown that the addition of free radical scavengers, such as 
superoxide dismutase, to the preservation fluid may be 
beneficial to the small bowel graft [74,139]. 
In a recent series of successful clinical SBT, a simple 
preservation method proved to be appropriate: simple 
core cooling of the graft with UW solution without exten- 
sive flushing of the capillary bed, followed by immersion 
in an ice bath. Even intraluminal washing was omitted, 
leaving the succes entericus in the graft, with no conse- 
quent infection from this practive [145]. Using UW solu- 
tion, satisfactory preservation for up to 16 h has been re- 
ported in humans [21]. 
Small bowel transplantation in humans 
Before CyA became available, attempts at clinical SBT 
were invariably unsuccessful. Failures were due to techni- 
cal complications, rejection, GVHD, and sepsis [57]. 
These discouraging results, and the availability of TPN, 
led to a diminished interest in SBT. 
Several successful SBT have been reported since CyA 
was introduced. Deltz et al. [24] reported a case of suc- 
cessful SBT using a 60-cm segment of jejunum and ileum 
harvested from the sister of the recipient. Although this 
graft was not rejected, the patient had severe diarrhea. 
The graft donor also developed chronic diarrhea. Nine at- 
tempts at SBT in seven children have resulted in one suc- 
cessful case in which the recipient is alive more than 
3 years after grafting. In all of the other patients the grafts 
had to be removed because of necrosis or because rejec- 
tion was uncontrollable [33]. The combined European ex- 
perience in SBT was recently reported by Schroeder et al. 
[126]: from March 1987 until July 1990,15 SBT were per- 
formed in 12 patients. Four grafts are presently function- 
ing, with patients independent of TPN. Immunosuppres- 
sion in these patients was with CyA and prednisone, 
usually supplemented with azathioprine and ALS. In one 
patient transient GVHD was encountered. Recently, a 
successful case of multiorgan transplantation including 
liver, pancreas, stomach, and small bowel was reported by 
Margreiter et al. [78]. Two minor rejection episodes of the 
bowel were encountered. Six months postoperatively all 
grafted organs functioned normally. 
McAlister et al. [83] performed isolated SBT, as well as 
combined small bowel-liver transplantation and abdomi- 
nal cluster transplantation; the isolated small bowel trans- 
plant had to be removed 15 days post-transplantation be- 
cause of uncontrollable rejection. Two of three patients 
with small bowel-liver transplantation are alive on CyA 
therapy, whereas the other died from a nonimmunologi- 
cal cause. One of two patients given an abdominal cluster 
transplant is well 7 months post-operatively, whereas the 
other died of a lymphoma. Todo et al. [145] reported on 
eight isolated SBT and eight small bowel-liver transplan- 
tations using FK 506 as the main immunosuppressant. 
Seven of the eight isolated small bowel transplants are 
functioning, and all patients who have their graft for more 
than 2 months are free of TPN. Of the eight small bowel- 
liver graft recipients, one died of sepsis and GVHD 
23 days post-transplantation. The other seven have grafts 
functioning from 7 to 23 months post-transplantation and 
are free of TPN. 
In all clinical cases, intestinal continuity was restored in 
stages. During the first operation, the proximal and distal 
ends, or the distal end of the graft only, were brought out 
as enterostomies. This allowed for macroscopic inspec- 
tion and graft biopsy in order to monitor graft rejection. 
Moreover, early alimentation of the graft or decpmpres- 
sion in the case of ileus are possible. In a second operation 
some weeks later, intestinal continuit$ was restored, after 
which oral feedings could be instituted [24, 36, 1451. It 
should be noted, however, that pediatric patients had an 
aversion to food and preferred tube feedings. 
Although in most of the cases reported the postopera- 
tive course was stormy, these successful cases suggest that 
SBT has become a clinical reality. 
Future prospects 
The reasons why the small bowel graft is particularly vul- 
nerable to rejection are now being delineated. The high 
rate of sepsis after SBT [37, 1261 has several causes. Im- 
munosupression given to the recipient compromises the 
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immunological barrier function of the bowel wall. Ische- 
mia and rejection increase the permeability of the graft by 
compromising the physical barrier. This has been shown 
to lead to bacterial translocation to the host [7,37]. Leak- 
age of toxins also occurs in this phase. This may be aggra- 
vated by the bacterial overgrowth in the graft en- 
countered after SBT [7,143]. 
Measures that maintain the gut barrier function after 
SBT will improve its outcome. Better immunosup- 
pressive drugs, like RAPA, may have a higher therapeutic 
index than CyA, although some believe that CyA, as the 
mainstay of immunosuppressive therapy, will provide sat- 
isfactory immunosuppression [78,126]. 
Several authors suggest that there may be an advant- 
age to combined small bowel-liver transplantation, and 
this has been supported by recently performed success- 
ful clinical small bowel-liver transplantation [36]. In rats, 
SBT performed 17 days after orthotopic liver transplan- 
tation led to long-term survival of the small bowel graft 
without any immunosuppression, whereas isolated small 
bowel grafts were rejected in 6-9 days [117]. Similar re- 
sults were reported by Zhong et  al. [160]. In a series of 
clinical small bowel and small bowel-liver transplanta- 
tions, however, the incidence of graft rejection in the first 
2 months after isolated SBT was lower than after com- 
bined small bowel-liver transplantation. The greater ease 
and safety of isolated SBT in this series indicates that 
combined small bowel-liver grafting should only be 
reserved for patients with coexisting liver failure [ 1451. 
Early institution of feeding of the graft helps to prevent 
disuse atrophy [72, 1091, and antibiotics reduce the bac- 
terial load of the gut. Other options that one map wish to 
experiment with include the administration of hormones 
trophic to the gut, such as epidermal growth factor and 
prostaglandin EZ, or the use of nutrients that are essential 
to the gut. One such nutrient that, in our opinion, deserves 
special attention is the amino acid L-glutamine. Several 
studies have demonstrated that glutamine is the principal 
fuel for enterocytes [134, 1521. There is only limited evi- 
dence that glutamine is essential for maintenance of nor- 
mal intestinal function [134]. However, the stress of a 
major operative procedure, combined with general anes- 
thesia, is followed by a decrease in circulating and muscle 
glutamine concentrations [ 1331. During injury or stress, 
glutamine may be a necessary dietary component to 
maintain gut structure and function. This is possibly due 
to the fact that glutamine is essential for nucleic acid bio- 
synthesis and might be especially important during criti- 
cal illness when the mucosal barrier becomes susceptible 
to breakdown [134]. It has been shown, for instance, that 
glutamine consumption by the intestinal tract is increased 
by 75% after laparotomy [134]. It has also been shown 
~~ ~~ ~~ ~ ~ 
that glutamine reduces bacterial translocation from the 
gut to the mesenteric lymph nodes following abdominal 
irradiation [ 1351. Moreover, glutamine supplementation 
of standard TPN solutions decreases the villous atrophy 
associated with long-term i. v. feeding [95], and bacterial 
translocation following TPN administration is attenuated 
when glutamine is added to the mixture. This diminished 
translocation was associated with a normalization of sIgA 
levels and a decrease in bacterial adherence to entero- 
cytes, suggesting that adding glutamine to the TPN solu- 
tion enhances gut immune function [2, 131. Preliminary 
results also indicate that glutamine is able to prevent the 
mucosal atrophy seen after heterotopic SBT [128]. Taken 
together, these findings indicate that glutamine could 
have important applications after SBT that are worth in- 
vestigating. 
Early detection of rejection is of vital importance in 
preserving barrier function and may benefit long-term 
graft function since it could delay and/or reduce fibrosis 
and chronic rejection. Several serum and urinary markers 
are now available which, in conjunction with histology, 
allow early recognition and treatment of rejection, and 
new markers are still being sought. For example, the 
enzyme diamino-oxidase is a potentially interesting mar- 
ker for both rejection and long-term graft function [112]. 
This enzyme, which is involved in the regulation of 
polyamine metabolism and probably also the regulation 
of mucosal growth, is produced mainly by mature entero- 
cytes in the villus tip [111]. It may have elevated levels in 
serum during acute ischemic injury of the small bowel mu- 
cosa [153] and, hence, may be useful in detecting acute 
rejection. Normally, after i. v. heparin administration, a 
rapid increase in plasma diamino-oxidase is seen [60,75]. 
These postheparin plasma diamino-oxidase levels are 
lowered in small bowel mucosal damage [20] and could 
prove to be a marker for graft function, something which 
deserves further study. 
Denervation, an inevitable consequence of SBT, 
causes hypersecretion from the crypts and diarrhea in the 
early stages after transplantation [86, 1501. It is thought 
that long-term impaired motility as a result ofdenerva- 
tion, although not hindering the pasage of food, is associ- 
ated with bacterial overgrowth. Increased chloride secre- 
tion [86, 1501, steatorrhea [107, 122, 1431, and increased 
fecal water content [143] are all thought to be long-term 
consequences of extrinsic denervation of the graft. 
Because these obstacles have now been traced and 
either removed or resolved, and because the first success- 
ful  clinical cases are being reported, there is reason to be 
optimistic about the future of clinical SBT. 
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